Physician Education: Bridging Clinical Research and Patient Care

CME Webcast

CME Webcast

Please read this page before participating in this activity. At the bottom of the page, click on “I have read these instructions and understand them,” to begin activity.

Please note: Adobe Flash is needed to view webcasts. To download the latest version of Adobe Flash Player, please go to http://get.adobe.com/flashplayer/.

A Practical Approach to the Management of Adverse Effects and Complications in the Treatment of HCV Infection: A Case-Based Discussion

Author(s): Kenneth E. Sherman, MD, PhD
Airdate: October 24, 2012 (34 minutes, 44 seconds)
CME hours: 0.50 (expires October 24, 2013)
Presented at: Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes
Co-Chair(s): Michael S Saag MD, Susanna Naggie MD, MHS

Grant support:

Request for grants has been made to commercial companies with competing products. Support is from the following:

PLATINUM SUPPORTER
Vertex Pharmaceuticals

GOLD SUPPORTERS
Abbott Laboratories
Gilead Sciences, Inc
Merck & Co, Inc

SILVER SUPPORTER
Janssen Therapeutics

CME Information:

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this enduring material for a maximum of 6.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.

Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

IAS–USA Board of Directors

Constance A. Benson, MD
Dr Benson serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare. She has received research grants awarded to the University of California San Diego from Gilead Sciences, Inc and ViiV Healthcare. Disclosure information for her spouse, Robert T. Schooley, MD, is indicated below. (Updated 04/26/15)

Peter Cassat, JD
Mr Cassat has no relevant financial affiliations to disclose. (Updated 05/30/12)

Judith S. Currier, MD
Dr Currier has no relevant financial affiliations to disclose. (Updated 10/23/14)

Carlos del Rio, MD
Dr del Rio has served as a consultant for InnaVirVax. (Updated 03/02/15)

Joel E. Gallant, MD, MPH
Dr Gallant has served as a consultant or advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Janssen Therapeutics, and Takara Bio, Inc; he has received research grants or contracts awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Sangamo BioSciences, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 06/09/14)

Roy M. Gulick, MD, MPH
Dr Gulick has no relevant financial affiliations to disclose. (Updated 04/16/15)

Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 05/13/15)

Jeanne M. Marrazzo, MD, MPH
Dr Marrazzo has served as a consultant or advisor to AstraZeneca. (Updated 12/22/14)

Douglas D. Richman, MD
Dr Richman has been a consultant to Gilead Sciences, Inc, Hera Therapeutics, and Monogram Biosciences, Inc. (Updated 04/21/15)

Michael S. Saag, MD
Dr Saag was awarded research grants, paid to his institution, from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and ViiV Healthcare. (Updated 03/11/15)

Robert T. Schooley, MD
Dr Schooley was awarded research grants, paid to his institution, from Boehringer Ingelheim Pharmaceuticals, Inc, and Bristol-Myers Squibb. His institution has received payment for his consultative advice and/or data monitoring committee service from Bristol-Myers Squibb, GlobeImmune, Gilead Sciences, Inc, and Monogram Biosciences. He serves as a consultant to CytoDyn and has stock options from CytoDyn and GlobeImmune. (Updated 04/26/15)

Paul A. Volberding, MD
Dr Volberding has served on scientific advisory boards for Bristol-Myers Squibb and Gilead Sciences, Inc.  He has also served on data safety monitoring boards for Merck & Co, Inc. (Updated 03/23/15)

Course Faculty and Staff:

Dr Dieterich has served as a consultant or scientific advisor and received honorarium from Archillion Pharmaceuticals, Inc, Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc, Gilead Sciences, Inc, Idenix Pharmaceuticals, Inc, Norvastis Pharmaceuticals Corp, and Roche Laboratories. (Updated 10/02/12)

Dr Kiser has no relevant financial affiliations to disclose. (Updated 10/10/12)

Dr Naggie has received research support from Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, Medtronic, Synexis, and Vertex Pharmaceuticals, Inc. She has served as a scientific advisor to Abbott Laboratories, Boehringer-Ingelheim, Janssen, and Vertex Pharmaceuticals, Inc. (Updated 10/11/12)

Dr Saag has received grants and research support from and/or has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 10/02/12)
 
Dr Shaw has no relevant financial affiliations to disclose. (Updated 10/16/12)

Dr Sherman has served as a consultant or scientific advisor to Fibrogen, Genentech, Inc, Kadmon, Merck Sharp and Dohme. He has served on data and safety monitoring boards for MedPace and Tibotec Therapeutics. He has received fees or royalties for written enduring materials, internet activities, and audiovisual activities from UpToDate and Springer Publishing. (Updated 10/05/12)

Dr Ward has no relevant financial affiliations to disclose. (Updated 10/16/12)

Dr Workowski has served as a scientific advisor for Gilead Sciences, Inc, Janssen Pharmaceuticals, Inc, and Vertex Pharmaceuticals, Inc. (Updated 10/05/12)

IAS–USA CME Staff

Donna M. Jacobsen, Executive Director, has no relevant financial affiliations to disclose (see above).

Cristin M. Toth, CME Project Manager, has no relevant financial affiliations to disclose. (Updated 04/13/15)

CME Evaluation and Claim Forms

After viewing this webcast, please submit your evaluation form to claim credit.

Contact Information

If you have any questions about this web-based CME activity, please contact the IAS–USA:
425 California Street
Suite 1450
San Francisco, CA   94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration@iasusa.org